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Glycerol kinase (GK) represents the primary entry of glycerol into glucose and triglyceride metabolism. Impaired
glucose tolerance (IGT) and hypertriglyceridemia are associated with an increased risk of diabetes mellitus and
cardiovascular disease. The relationship between glycerol and the risk of IGT, however, is poorly understood. We
therefore undertook the study of fasting plasma glycerol levels in a cohort of 1,056 unrelated men and women of
French-Canadian descent. Family screening in the initial cohort identified 18 men from five families with severe
hyperglycerolemia (values above 2.0 mmol/liter) and demonstrated an X-linked pattern of inheritance. Linkage
analysis of the data from 12 microsatellite markers surrounding the Xp21.3 GK gene resulted in a peak LOD score
of 3.46, centered around marker DXS8039. In addition, since all of the families originated in a population with
a proven founder effect—the Saguenay Lac-St.-Jean region of Quebec—a common disease haplotype was sought.
Indeed, a six-marker haplotype extending over a region of 5.5 cM was observed in all families. Resequencing of
the GK gene in family members led to the discovery of a N288D missense mutation in exon 10, which resulted in
the substitution of a highly conserved asparagine residue by a negatively charged aspartic acid. Although patients
with the N288D mutation suffered from severe hyperglycerolemia, they were apparently otherwise healthy. The
phenotypic analysis of the family members, however, showed that glycerol levels correlated with impaired glucose
metabolism and body-fat distribution. We subsequently noted a substantial variation in glycerolemia in subjects of
the initial cohort with normal plasma glycerol levels and demonstrated that this variance showed significant family
resemblance. These results suggest a potentially important genetic connection between fasting glycerolemia and
glucose homeostasis, not only in this X-linked deficiency but, potentially, in individuals within the “normal” range
of plasma glycerol concentrations.
Introduction
Glycerol is an important intermediate of glucose and
lipid metabolism by virtue of its ability to support gly-
cogenesis in various systems, as well as serving as a pre-
cursor for the synthesis of triglycerides (TG) and other
glycerolipids (Rognstad et al. 1974; Baba et al. 1995;
McCabe 1995). Oral administration of glycerol has been
demonstrated to result in increased serum glucose levels,
gluconeogenesis, or both (Catron and Lewis 1929; Som-
mer et al. 1993), similar to the changes observed in var-
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ious pathological situations such as type 2 diabetes mel-
litus (DM) (MIM 125853). It has also been shown that
obese subjects have increased levels of plasma glycerol
and increased glycerol turnover when compared with
lean individuals (Chakrabarty et al. 1984; Jansson et al.
1992). These observations indicate the potential impor-
tance of glycerol homeostasis in healthy individuals, as
well as in patients with abnormalities in glucose or lipid
metabolism who are at higher risk of DM or coronary
artery disease.
The glycerol kinase (GK) enzyme is a primary can-
didate for the control of glycerol levels, since it consti-
tutes glycerol’s entry into metabolic pathways. Genetic
abnormalities involving the GK gene, which is located
on chromosome Xp21.3 (Davies et al. 1988; Guo et al.
1993; Walker et al. 1993), have been classified as either
complex or isolated deficiencies. The complex GK de-
ficiency (GKD) is a contiguous-gene syndrome involving
the GK locus, as well as the Duchenne muscular dys-
trophy (MIM 310200) gene locus, the adrenal hypo-
plasia congenita (MIM 300200) gene locus (McCabe
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Figure 1 Pedigree drawings of three of the families whose members have severe hyperglycerolemia. Women (dotted circles) and men
(blackened squares) with elevated plasma glycerol levels are indicated. The number under each symbol is the individual’s identification number,
and the numbers below those are the plasma glycerol levels (mmol/liter), where available.
1995), or both. In contrast, isolated GKD, which in-
cludes juvenile and adult forms, results from either point
mutations or small rearrangements within the GK gene
(McCabe 1995). The adult form is characterized by a
phenotype of hyperglycerolemia (MIM 307030), often
detected as a pseudohypertriglyceridemia, since the en-
zymatic measurement of TG is generally inferred from
that of glycerol generated as a product of a lipolysis
reaction. Apart from pseudohypertriglyceridemia, how-
ever, the clinical expression of the adult form of isolated
GKD is not well documented, mainly because of the
small number of clinically and genetically heterogene-
ous families described in previous reports (Rose and
Haines 1978; Blomquist et al. 1996; Walker et al. 1996;
Romero et al. 1997; Sjarif et al. 1998). None of these
studies was designed to examine—or had the power to
examine—the broader metabolic implications of raised
plasma glycerol levels in the fasting state. In the present
study, we report the findings of our clinical and molec-
ular genetic examinations of the largest group of indi-
viduals with familial hyperglycerolemia ever reported.
These individuals were identified from a cohort of 1,056
unrelated French Canadians. We provide evidence that
fasting glycerolemia is a significant predictor of im-
paired glucose tolerance (IGT) in these families whose
members have hyperglycerolemia, and we propose a po-
tentially important genetic connection between glycerol
and glucose homeostasis, even in what is considered as
the normal range of plasma glycerol concentration.
Subjects and Methods
Subjects
From a large sample of 1,056 individuals of French-
Canadian descent aged >18 years screened for plasma
glycerol concentration, 5 men presented with plasma
glycerol values 12.0 mmol/liter. Screening of their fam-
ilies identified a total of 18 men demonstrating extremely
elevated plasma glycerol levels (range 2.9–6.2 mmol/li-
ter). In addition, 14 obligate female carriers were found
to be dysglycerolemic, presenting intermediate plasma
glycerol levels of 0.21–0.82 mmol/liter, whereas all other
family members showed plasma glycerol concentrations
!0.2 mmol/liter. On the basis of the pedigree data shown
in figure 1, it was clear that the severe hyperglycerolemia
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Figure 2 The exonic structure of the Xp GK gene and location of sequence polymorphisms and N288D mutation. Boxes show each exon
and its length in base pairs (intron length not drawn to scale). Primers used to amplify each exon are shown over and under the exonic structure
(arrowheads). The updated exon-intron boundaries of exons 9, 10, 11, and 17 are shown in the upper part of the diagram, with uppercase
letters indicating exons and lowercase letters indicating introns. The two PAC clones used for the genomic structure determination are illustrated
by the two lines at the bottom of the figure. All details regarding primer sequences and annealing temperatures are available on the Chicoutimi
Hospital Lipid Research Group and Whitehead Institute/MIT Center for Genome Research GK Web sites.
phenotype segregated as a simple X-linked trait. All par-
ticipants in the present study gave written informed con-
sent. This project received the approval of the Chicou-
timi Hospital Ethics Committee.
Linkage to the Xp21.3 Locus
Genomic DNA was obtained from peripheral blood
lymphocytes for the genotyping of 13 affected men, 5
obligate female carriers, and 23 relatives from the fam-
ilies of the probands with severe hyperglycerolemia. A
total of 12 microsatellite markers in the region of the
GK gene were genotyped in these five families. The
markers were as follows, in order: DXS989, DXS8039,
DXS1214, DXS1036, DXS1067, DXS1219, DXS997,
DXS8090, DXS8025, DXS8113, DXS8042, and
DXS8012. Genotypes for these markers were obtained
by PCR with fluorescently labeled primers. Each locus
was amplified separately, and the individual PCR prod-
ucts were then multiplexed into panels by pooling on
the basis of allele size range and fluorescent label. Ali-
quots of the multiplexed samples were mixed with either
Tamra-labeled GENESCAN 500 and GENESCAN 2500
(PE Applied BioSystems) or rhodamine-labeled
MapMarkers (Bioventures) prior to electrophoresis on
ABI 377 sequencers (PE Applied BioSystems). The ge-
notyping gels were analyzed in an automated system
developed at the Whitehead Institute/MIT Center for
Genome Research, as described elsewhere (Rioux et al.
1998).
Genomic Structure of the GK Gene
Genomic sequences were sought for the intronic
regions surrounding exons 9, 10, 11, and 17. P1 artificial
chromosome (PAC) clone RPCI-5.931_C_24 containing
exons 9, 10, and 11 was identified by use of primer pairs
GK08 and GK12. PAC clone RPCI-5.1150_E_8 con-
taining exon 17 was identified by use of primers GK17F
and GK17R. Direct sequencing of introns 9 and 10 from
clone RPCI-5.931_C_24 by means of specific exonic
primers (GK9F, GK10F, and GK10R) was carried out
with the Big Dye terminator cycle sequencing kit (PE
Applied BioSystems) under the following conditions: de-
naturation at 957C for 5 min, then 957C for 30 s, 507C
for 20 s, and 607C for 4 min, for 100 cycles.
To obtain the genomic sequence for intron 17, a single
colony of clone RPCI-5.1150_E_8 was diluted in 100
ml of water and was used as template for PCR ampli-
fication. An amplicon covering exon 17 through exon
18 was obtained with primers GK17_F and GK18_R
(fig. 2) with Platinum Taq High Fidelity (Life Technol-
ogies). The PCR product was purified by the solid-phase
reversible immobilization method (Hawkins et al. 1994)
and then sequenced with the DYEnamic Energy Transfer
primer kit (Amersham Pharmacia Biotech).
All sequencing reactions were run on ABI377 auto-
mated sequencers (PE Applied BioSystems); the gel files
were processed by the BASS and Trout software (avail-
able on the Whitehead Institute/MIT Center for Genome
Research FTP site) and then were assembled and ana-
lyzed with the use of the Staden (GAP4) software pack-
age (Staden 1996). All details regarding primer se-
quences and annealing temperatures are available on the
Chicoutimi Hospital Lipid Research Group and White-
head Institute/MIT Center for Genome Research GK
Web sites.
GK Mutation Screening
The screening for mutations in the GK gene was first
performed by resequencing this gene in nine affected
individuals, four obligate carriers, and three unaffected
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relatives from the five families described above. Intronic
primers used were previously published (Sargent et al.
1994) or designed from the sequence determined in the
present study with the use of the Primer 3.0 software,
which is available on the Whitehead Institute/MIT Cen-
ter for Genome Research server. Sequencing reactions
with the DYEnamic Energy Transfer primer kit were
performed and analyzed as described above. Regions in
which sequence polymorphisms were discovered were
resequenced in 9 other affected individuals, 10 obligate
carriers, unaffected relatives from the GK families, and
50 independent individuals from the initial cohort as
population controls.
Plasma Glycerol and Other Biological Measurements
Blood samples were drawn while the individual was
at rest after a 12-h overnight fast. The blood was drawn
from an antecubital vein into tubes containing EDTA.
Specimens were centrifuged within 1 h, and the sepa-
rated plasma was frozen (2807C) until analysis. TG and
free fatty acid (FFA) levels were measured by enzymatic
assays (McNamara and Schaefer 1987). Plasma glycerol
concentrations were measured with an analyzer Techn-
icon RA-500 (Bayer Corporation), and enzymatic rea-
gents were obtained from Randox (Randox Laborato-
ries). Glycerol measurements were calibrated with
reference standards purchased from Sigma. Intra- and
interassay coefficients of variation were 1.3% and 2.5%,
respectively, for levels of 0.1 mmol/liter and were 0.9%
and 1.7% for levels of 1.0 mmol/liter. Waist and hip
circumferences (Lohman et al. 1988), body weight,
height, and body-mass index were recorded. Percentage
of body fat was estimated by bioelectrical impedance
(Baumgartner et al. 1990). Family history of DM was
defined as the presence of a confirmed diagnosis in a
first-degree relative. An oral glucose–tolerance test
(OGTT) was performed in the original cohort of 1,056
individuals and in the families of the five GK carrier
probands; we used a 75-g glucose load (Richterich and
Dauwalder 1997), and plasma glucose concentration
was enzymatically measured (Richterich and Dauwalder
1971). IGT and DM were defined according to the
World Health Organization (WHO Study Group on Di-
abetes 1987). Fasting insulinemia was measured by ra-
dioimmunoassay with polyethylene glycol separation
(Desbuquois and Aurbach 1971).
Statistical Analysis
Multipoint parametric linkage analysis was performed
by the GENEHUNTER software package (Kruglyak et
al. 1996). Marker order and genetic distances used in
the analysis were based on an integration of the pub-
lished genetic map (CEPH-Genethon Database) and ra-
diation-hybrid mapping information obtained by the
Genebridge 4 hybrid panel (Gyapay et al. 1996). On the
basis of the number of cases observed in the population,
GK disease-allele frequency was estimated at .001,
whereas the values for male penetrance of .999 and fe-
male penetrance of .900 and .999 (heterozygotes and
homozygotes, respectively) were estimated from the fam-
ily data. Group differences for plasma glycerol concen-
trations and other continuous variables were examined
by the Student’s unpaired two-tailed t-test. Linear re-
gression models were used to assess the relationship be-
tween the dependent variables (2-h glucose following a
75-g oral absorption or correlates of body-fat accu-
mulation) and fasting glycerolemia. The distribution of
plasma TG and insulin levels was normalized by log10
transformation. Analyses were performed by the SPSS
package (release 6.1, SPSS).
After having excluded families of subjects bearing the
N288D mutation, calculation of familial resemblance of
plasma glycerol concentrations in the fasting state was
performed for a total of 652 individuals that arose from
the nuclear families of 174 randomly selected patients
of the initial cohort representing all deciles of fasting
glycerol values. Before analyses, glycerol data were ad-
justed for age by use of sex-specific regressions, and the
residuals from these regressions were standardized to a
mean of 0 and a standard deviation of 1. The stan-
dardized residuals were used to assess the degree of fa-
milial resemblance by computing the intraclass corre-
lation (r) as previously described (Bogardus et al. 1986;
Pe´russe et al. 1997). This correlation was calculated by
computing the ratio of the between-family variance over
the sum of the within- and between-family variances
estimated with a random effect model of analysis of
variance (Bogardus et al. 1986).
Results
Linkage to Xp21.3 of the Severe Hyperglycerolemia
Phenotype
We genotyped 12 microsatellite markers, covering ∼25
cM in the region of Xp21.3, among the five pedigrees
that described affected individuals. Multipoint para-
metric linkage analysis of the genotype data resulted in
a peak LOD score of 3.46 centered at marker DXS8039,
the closest marker to the GK gene. As all families orig-
inated from a population with a proven founder effect
(Gradie et al. 1998), a common disease haplotype was
sought. Indeed, a six-marker haplotype consisting of
markers DXS8039, DXS1214, DXS1036, DXS1067,
DXS1219, and DXS997 (alleles 151, 210, 145, 222,
230, and 107, respectively) was observed in all families.
This haplotype extended over a region of 5.5 cM.
Genomic Structure of the GK Gene
Since the GK gene is located near the linkage peak,
clearly indicating its likely involvement in this pheno-
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Figure 3 Alignment of the predicted amino acid sequence for
the N288D mutant with the wild-type sequences from different or-
ganisms. Abbreviations: ecoli, E. coli; pseae, Pseudomonas aeruginosa;
entca, Enterococcus casseliflavus; haein, Haemophilus influenzae;
bacsu, Bacillus subtilis; yeast, Saccharomyces cerevisiae; mycge, My-
coplasma genitalium; entfa, Enterococcus faecalis; mycpn, Myco-
plasma pneumoniae; syny3, Synechocystis PCC6803. Dashes represent
gaps introduced in the sequences to maximize alignment.
type, we set out to obtain intronic sequences surrounding
exons 9, 10, 11, and 17 to design primers to complete
the set of previously reported oligonucleotides for mu-
tation screening (Sargent et al. 1994). This sequencing
led to the discovery (fig. 2) of a small intron within what
had previously been described as exon 9 (Sargent et al.
1994). Specifically, we found an insert of 394 bp located
after the 36th nucleotide of exon 9, suggesting that the
originally described exon actually consists of two exons
of 36 and 68 bases in length, respectively, that we have
named 9A and 9B. This correction of the published ge-
nomic structure is supported by a recent report (Sjarif
et al. 1998). In addition, when the sequence obtained
for intron 10 was aligned with the published cDNA se-
quence, it was discovered that the splice junctions had
been incorrectly defined, so that the last 12 bases of exon
10 were in fact encoded by exon 11. Furthermore, when
the entire intron was sequenced, rather than being 18
kb in length, as originally believed, it was found to be
456 bp.
Identification of a Missense Mutation in Exon 10
within Families with Severe Hyperglycerolemia
All 20 GK exons and their corresponding intron-exon
boundaries were screened for mutations. Four nucleotide
positions were found to have sequence differences be-
tween the affected men and their unrelated control in-
dividuals, and, at these same positions, the obligate fe-
male carriers were heterozygous. Specifically, two of
these sites were discovered within the introns and two
within the exons (fig. 2). Neither of the intronic nucle-
otide changes is expected to lead to a functional differ-
ence. On the basis of the predicted amino acid sequence
for this gene, the nucleotide change in exon 3 is silent,
whereas the base change in exon 10 results in a missense
mutation. Specifically, this latter change results in a tran-
sition of an adenine to a guanine, and this mutation
(N288D) leads to the substitution of a small polar as-
paragine for a negatively charged aspartic acid (fig. 3).
Screening of the remaining family members demon-
strated that this mutation was restricted to the 18 af-
fected men and 14 obligate female carriers and was not
present in the normoglycerolemic individuals examined
from the original cohort. This was not true of the other
three nucleotide changes, since they were found in a
sample of 50 normoglycerolemic controls at frequencies
110%. It is important to note that asparagine 288 of
GK is extremely well conserved in many different spe-
cies, including Haemopilus influenzae, Mycoplasma
pneumoniae, Escherichia coli, yeast, and mouse, as well
as human (fig. 3) (Pettigrew et al. 1988, 1998).
Phenotypic Expression of the N288D Mutation:
Association of Fasting Glycerol Concentration with IGT
and Abdominal Obesity
Monitoring of plasma glycerol levels at 3–6-mo in-
tervals in individuals with the N288D mutation dem-
onstrated that the hyperglycerolemia was permanent, re-
sulting in values 12.5 mmol/liter in men and 10.2 mmol/
liter in women. Despite severe hyperglycerolemia,
individuals with the N288D mutation were apparently
healthy. In contrast to what is observed in the cases of
contiguous-gene-deletion syndrome involving the GK
gene, none of the hyperglycerolemic patients of the pre-
sent study had evidence of muscular or adrenal involve-
ment. Review of the medical histories did not show any
previous episode of severe illness (vomiting, acidemia,
stupor, or unconsciousness), as reported with the juvenile
form of isolated GKD (McCabe 1995). As would be
expected, the N288D carriers also showed important
pseudohypertriglyceridemia when compared with un-
affected relatives. Interestingly, even after correction for
free glycerol, GK patients tended to remain hypertrig-
lyceridemic (plasma TG 12.0 mmol/liter).
The 18 affected men and the 14 obligate female car-
riers identified were matched with unaffected relatives
by age (55 years) and by sex; their characteristics are
compared in table 1. This comparison demonstrated that
the N288D mutation was associated with significantly
higher body-mass index, waist circumference, and total
Gaudet et al.: Hyperglycerolemia and Glucose Metabolism 1563
Table 1
Characteristics of Carriers of the N288D GK Gene Mutation and of Their Unaffected Relatives
VARIABLE
MEN WOMEN
N288D
Carriers
Unaffected
Relatives P
N288D
Carriers
Unaffected
Relatives P
Number 18 18 14 14
Age (years) 46.4 5 14.2 42.0 5 18.8 .32 44.9 5 13.5 43.7 5 17.8 .87
Uncorrected triglyceride (mmol/liter)a 6.26 5 1.13 2.05 5 .54 !.0001 2.84 5 1.20 1.30 5 .65 .0002
Glycerol (mmol/liter) 3.99 5 .71 .10 5 .04 !.0001 .54 5 .14 .10 5 .02 !.0001
Corrected triglyceride (mmol/liter)a 2.27 5 .75 1.95 5 .53 !.0001 2.31 5 1.22 1.19 5 .67 .03
Free fatty acid (mmol/liter) .77 5 .22 .57 5 .25 .01 1.29 5 .35 .76 5 .17 .0004
Fasting glucose (mmol/liter) 5.2 5 .74 4.8 5 .31 .13 5.0 5 .7 4.6 5 .3 .1
2-h glucose following OGTT (mmol/liter) 7.9 5 3.1 5.8 5 1.6 .02 7.0 5 6.1 5.0 5 2.1 .04
Fasting insulin (mU/liter)a 13.3 5 14.0 15.1 5 14.8 .62 12.2 5 13.1 9.0 5 3.4 .6
Waist girth (cm) 97.7 5 9.3 88.1 5 12.3 .01 88.5 5 3.8 79.8 5 5.8 .03
Body mass index (kg/m2) 27.9 5 4.1 24.9 5 3.9 .03 28.1 5 5.5 23.1 5 2.3 .001
Total body fat (%) 27.1 5 7.2 22.9 5 7.6 .01 46.8 5 8.1 33.9 5 11.3 .001
NOTE.—Values are means 5 SD.
a Geometric mean, P after log transformation.
body fat, increased fasting plasma FFA concentrations,
and a higher mean 2-h glucose concentration following
an OGTT. Furthermore, analysis of plasma glucose ho-
meostasis, as well as anthropometric indices of abdom-
inal obesity in men carrying a N288D mutation, showed
that 12 of the 18 affected men met the criteria of either
DM or IGT (fig. 4A). Among the six subjects with nor-
mal 2-h glucose levels, four men showed elevated fasting
insulin values, which suggests that they were insulin re-
sistant (data not shown). It was also observed that there
were significant differences in glycerol levels among
N288D bearers. As illustrated in figures 4A and 4B,these
differences were shown to be important correlates of
body-fat accumulation and glucose concentrations. Spe-
cifically, we observed that 68.9% of the variance in 2-
h glucose values ( ) and 45.2% of the varianceP ! .0001
in waist circumference ( ) could be explained byP ! .001
the variance in glycerolemia among these subjects. Com-
pared with glycerol, variations in plasma fasting FFA or
insulin concentrations explained a significantly lower
proportion of the variance in 2-h glucose and in waist
circumference (data not shown).
Genetic and Phenotypic Analysis of the
Normoglycerolemic Population
In light of the genetic control of glycerolemia observed
in the GKD families, as well as the association with IGT,
analyses of the original cohort excluding the severe hy-
perglycerolemic individuals were also performed. Spe-
cifically, analyses of familial resemblance in the original
cohort revealed that there was six times more variance
in fasting plasma glycerol levels between than within
families (fig. 5). If we assume that the resemblance ex-
plained by belonging to the same pedigree is entirely
defined by genetic factors, the maximal heritability of
glycerolemia in the fasting state was estimated at 58%
(95% confidence interval [CI] 52%–64%). In addition,
as seen in the presence of the N288D GK mutation, a
trend between mean glycerol concentration and the de-
gree of glucose intolerance was observed in normogly-
cerolemic individuals (fig. 4C).
Discussion
It is likely that there are hundreds of different genes
involved in the modulation of plasma glucose and lipid
homeostasis. Among them are genes involved in the reg-
ulation of glycerol metabolism, since these pathways
contribute directly or indirectly to cellular energy me-
tabolism by providing mitochondria with substrate for
oxidative phosphorylation (McCabe 1994). In this re-
gard, GK plays a pivotal role, since it constitutes the
entry of glycerol into metabolism, catalyzing the phos-
phorylation of glycerol by adenosine triphosphate (ATP)
to yield glycerol 3-phosphate and adenosine diphosphate
(McCabe 1994, 1995). Although glycerol is a well ac-
cepted indicator of lipolysis and is a gluconeogenic pre-
cursor (Rognstad et al. 1974), the relationship between
glycerol and glucose homeostasis is complex and not yet
completely elucidated. One way to further this knowl-
edge is to study cases of hyperglycerolemia to establish
the effect of glycerol levels in this extreme phenotype on
the other metabolic pathways, and then examine
whether similar effects can be found in normoglycero-
lemic individuals.
Following this approach, we describe here the mo-
lecular and clinical characteristics of the largest sample
of individuals with familial hyperglycerolemia ever re-
ported. Importantly, all families exhibiting this severe
phenotype were identified through a systematic screen-
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Figure 4 Association of plasma glycerol with correlates of glucose intolerance. A, B, Among the 18 men bearing the N288D mutation,
glycerol was a significant correlate of 2-h glucose following a 75-g oral load ( , ) and waist girth ( , ). Five2 2r = 0.689 P ! .0001 r = 0.452 P ! .0001
men with previously diagnosed DM did not undergo an OGTT. Individuals with fasting insulin concentrations above 15 mU/liter (A, black
circles) are indicated. C, Mean plasma glycerol concentrations (595% CI) according to the magnitude of glucose tolerance in subjects with or
without severe hyperglycerolemia due to the N288D mutation. “Normal” defines the category of subjects with normal glucose tolerance (2-h
glucose !7.8 mmol/liter following a 75-g oral glucose absorption). “IGT” identifies impaired glucose tolerance (2-h glucose 7.8–11.0 mmol/
liter), whereas “DM” denotes the presence of criteria of type 2 DM (2-h glucose >11.1 mmol/liter) during the OGTT. The ratio of normal/
IGT/DM in N288D individuals was significantly different from that of noncarriers (x2 = 14,3; ).P = .001
ing of fasting glycerol levels in a large number of in-
dividuals of French-Canadian descent. The homoge-
neity of this group of patients is clearly demonstrated
by our observation that all affected individuals bear the
same N288D mutation in the GK gene, present on a
haplotype that is common to all GKD families. The
study of this rare deficiency in glycerol metabolism dem-
onstrated that although all individuals bearing the
N288D mutation were hyperglycerolemic, significant
interindividual variations in glycerolemia were ob-
served, and these differences were found to explain an
important part of the variance observed in glucose tol-
erance and abdominal obesity—a feature not reported
in previous studies on familial hyperglycerolemia.
The mechanisms by which the N288D mutation
could result in hyperglycerolemia remain to be eluci-
dated. GK, also known as ATP:glycerol 3-phospho-
transferase, is a member of the sugar kinase–heat shock
70–actin superfamily of enzymes (Pettigrew et al. 1988).
The defined structure for the members of this superfam-
ily consists of a deep and narrow cleft, the enzymatic
active site, that separates two large domains (Pettigrew
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Figure 5 Familial resemblance of plasma glycerol concentrations in the fasting state. One hundred seventy-four individuals were randomly
selected from the initial cohort of 1,056 individuals. Analyses were performed on these individuals and their family members after we excluded
families who showed evidence of X-linked transmission of hyperglycerolemia caused by the N288D mutation in the GK gene. The families are
ranked according to plasma glycerol concentration in the fasting state. The range of mean glycerolemia between and within families is shown
(hatched bars, right). In the absence of GK gene mutation, a highly significant ( ) F ratio of 6.3 was observed, suggesting that thereP ! .0001
is over six times more variance between families than within them for plasma glycerol levels in the fasting state. The maximal heritability of
glycerolemia in the fasting state has been estimated at 58% (95% CI 52%–64%) in the absence of severe hyperglycerolemia. The dashed line
denotes median and geometric mean of plasma glycerol concentration (0.075 mmol/liter) observed in the initial cohort of 1,056 individuals
(the probands).
et al. 1988). These large domains are subdivided into
subdomains; the two subdomains that are topologically
identical to the common ATP core of hexokinase are
termed IA and IIA. Asparagine 274 in the GK enzyme
of E. coli, the residue corresponding to asparagine 288
in humans, is located in subdomain IIA (Pettigrew et
al. 1988). Although this residue is not believed to be
directly involved in the catalytic site, since it has no
direct contact with either the glycerol or ATP molecules,
it is possible that the change to a negatively charged
aspartic acid in our GKD patients could alter the struc-
ture of subdomain IIA. Indeed, it is believed that en-
zymatic activity is coupled to a conformational change
in which the two domains close around the ATP mol-
ecule (Pettigrew et al. 1998). Specifically, the change
from an uncharged asparagine residue to a negatively
charged aspartate could possibly impede the domain
closure central to the catalytic mechanism.
Following the findings in the severe hyperglycero-
lemic families, examination of the large cohort of nor-
moglycerolemic individuals suggested that fasting
plasma glycerol concentrations have an important fa-
milial component in humans. This finding is potentially
important, since glycerol is usually only considered as
an intermediate metabolite, its concentration being af-
fected by multiple factors such as the degree of glycerol
released by lipolysis, the rate of glyconeogenesis or gly-
cogenolysis, obesity, starvation, exercise, the use of
pharmaceutical preparations, and numerous patholog-
ical conditions (Frank et al. 1981; Sommer et al. 1993;
McCabe 1995). Despite the variety of environmental
factors affecting glycerol concentrations, we found that
the heritability of fasting glycerolemia could be as high
as 58% in humans. This indicates an important genetic
control of glycerol levels in the normal population.
Moreover, the trend observed between mean glycerol
concentration, the waist girth, and the degree of glucose
intolerance suggests that the genetic control of glycerol
levels may potentially have a role to play in glucose and
fat metabolism. Although the N288D is unlikely to play
a role in the general population (it was not present in
any of the normoglycerolemic individuals we tested),
we would postulate that it is likely there are common
genetic variants in the glycerol metabolic pathway af-
fecting glucose and fat homeostasis.
Overall, numerous factors favor the possibility of a
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causative association between glycerol and fat metab-
olism (Rognstad et al. 1974; Chakrabarty et al. 1984;
Baba et al. 1995; McCabe 1995). Indeed, studies in lean
and obese subjects showed that there was a direct cor-
relation between plasma glycerol concentration and
glycerol turnover, and that both were increased in obese
subjects when compared with lean individuals (Chak-
rabarty et al. 1984). In another interesting study, Huq
et al. (1997) have generated GK-deficient mice by gene
targeting. In their study, mutant male mice appeared
normal at birth and exhibited severe hyperglycerolemia
with altered fat metabolism and elevated FFA concen-
trations. However, this model was probably closer to
the human complex GKD phenotype, since GK-deficient
male mice showed postnatal growth retardation, au-
tonomous glucocorticoid synthesis, and death by 3–4 d
of age, whereas heterozygous female individuals were
healthy and biochemically normal.
The possibility of a causative association between
glycerol and glucose metabolism is also supported by
several factors, including the fact that glycerol is an
important glucose precursor (Baba et al. 1995). It is
likely that the mechanisms involved in the glycerol-de-
rived gluconeogenesis increase are the result of accel-
erated lipolysis, as well as of altered intrahepatic han-
dling of glycerol (Yilmaz et al. 1987). In a recent study
that used a rat model, the gene encoding the bacterial
form of GK has been introduced in beta cells of islets
of Langerhans by use of adenovirus systems (Noel et
al. 1997). The results showed that glycerol appeared to
be a highly effective insulin modulator. However, it is
not clear if human beta cells exhibit sufficient GK ac-
tivity to allow significant metabolism of the substrate
(Noel et al. 1997). In another interesting study, Yang
et al. (1999) have observed that glycerol activates glu-
cose-responsive neurons by using a regulatory mecha-
nism similar to that of pancreatic beta cells and could
therefore act indirectly as an hypothalamic glucose sen-
sor. These data suggest that beyond glycerol-derived glu-
coneogenesis, glycerol is likely to play a fine regulatory
role (Huq et al. 1997; Eto et al. 1999; Yang et al. 1999).
In this regard, glycerolemia turned out to be a better
predictor of 2-h glucose than FFAs or insulinemia in
carriers of mutation N288D. Although quite convinc-
ing, the positive relation between glycerol and 2-h glu-
cose observed in N288D carriers is made on the basis
of clinical data only and the possibility of a causative
association between the N288D GK variant and 2-h
glucose would be better supported by direct kinetic as-
sessment of the effect of the mutation and transfection
of the amino acid substitution into tissue-culture cells.
Furthermore, the notion whether the association of glyc-
erol with IGT is independent of variations in other cov-
ariates such as insulinemia, FFAs, or anthropometric
variables remains to be verified in a larger cohort, rep-
resentative of individuals with normal glycerolemia.
In conclusion, the current study of a large sample of
unrelated individuals and of a homogeneous group of
patients with a rare deficiency in glycerol metabolism
suggests an important genetic connection between glyc-
erol metabolism and the level of glucose tolerance. In-
deed, familial resemblance of glycerol levels suggests
that there likely exist common genetic factors in the
general population that would explain some of the dif-
ferences in plasma glycerol levels. It will thus be im-
portant to find the common allelic variants and their
functional consequences in GK and the other genes in-
volved in the glucose and lipid metabolic pathways, in
order to better understand the various processes that
determine the body’s ability to regulate blood glucose
as well as body-fat accumulation and distribution.
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